Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison J Moskowitz

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Haematologica|July 17, 2025
Fit, unfit, or frail? Now easier to tell for Hodgkin lymphomaAlison J Moskowitz
Journal of Oncology Practice|March 13, 2019
Practical Treatment Approach for Angioimmunoblastic T-Cell LymphomaAlison J Moskowitz
Haematologica|April 2, 2026
Relapsed Hodgkin disease: Should all patients receive an autologous stem cell transplant? - the CONAlison J Moskowitz
Hematology. American Society of Hematology. Education Program|December 9, 2022
Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?Alison J Moskowitz
Hematology. American Society of Hematology. Education Program|December 4, 2018
Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapyAlison J Moskowitz
Current Oncology Reports|June 19, 2012
Novel agents in Hodgkin lymphomaAlison J Moskowitz
Current Hematologic Malignancy Reports|May 11, 2017
Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?Niloufer Khan, Alison J Moskowitz
Cancers|February 11, 2023
Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell LymphomaRobert Stuver, Alison J Moskowitz
Current Opinion in Oncology|July 15, 2024
What is the best salvage therapy for Hodgkin lymphoma?Efrat Luttwak, Alison J Moskowitz
Leukemia & Lymphoma|November 5, 2016
Targeting histone deacetylases in T-cell lymphomaAlison J Moskowitz, Steven M Horwitz
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Haematologica|July 17, 2025
Fit, unfit, or frail? Now easier to tell for Hodgkin lymphomaAlison J Moskowitz
Journal of Oncology Practice|March 13, 2019
Practical Treatment Approach for Angioimmunoblastic T-Cell LymphomaAlison J Moskowitz
Haematologica|April 2, 2026
Relapsed Hodgkin disease: Should all patients receive an autologous stem cell transplant? - the CONAlison J Moskowitz
Hematology. American Society of Hematology. Education Program|December 9, 2022
Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?Alison J Moskowitz
Hematology. American Society of Hematology. Education Program|December 4, 2018
Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapyAlison J Moskowitz
Current Oncology Reports|June 19, 2012
Novel agents in Hodgkin lymphomaAlison J Moskowitz
Current Hematologic Malignancy Reports|May 11, 2017
Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?Niloufer Khan, Alison J Moskowitz
Cancers|February 11, 2023
Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell LymphomaRobert Stuver, Alison J Moskowitz
Current Opinion in Oncology|July 15, 2024
What is the best salvage therapy for Hodgkin lymphoma?Efrat Luttwak, Alison J Moskowitz
Leukemia & Lymphoma|November 5, 2016
Targeting histone deacetylases in T-cell lymphomaAlison J Moskowitz, Steven M Horwitz
Pageof 10